Organon, a subsidiary of the Dutch chemical and pharmaceutical company Akzo, will make further alterations to its research activities in the Netherlands, Scotland and France, reports Reuters.
The firm's research unit in Riom, France will close because it has become too small. The research programs in the Netherlands and Scotland, however, will be strengthened, which will result in more efficient use of resources, the firm said.
The Scottish site will focus on all psychotherapeutic treatments, which will need an increase in staff there. In the Netherlands, Organon will carry out its gynecology, arthritis and thrombosis research.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze